Research Article

Inhibition of Brain Swelling after Ischemia-Reperfusion by β-Adrenergic Antagonists: Correlation with Increased K+ and Decreased Ca2+ Concentrations in Extracellular Fluid

Dan Song, Junnan Xu, Ting Du, Enzhi Yan, Leif Hertz, Wolfgang Walz, and Liang Peng

1 Laboratory of Brain Metabolic Diseases, Institute of Metabolic Disease Research and Drug Development, China Medical University, No.92BeierRoad, Heping District, Shenyang 110001, China
2 Departments of Psychiatry and Pharmacology, University of Saskatchewan, Saskatoon, SK, Canada

Correspondence should be addressed to Liang Peng; hkkid08@yahoo.com

Received 31 May 2014; Revised 3 September 2014; Accepted 10 September 2014; Published 13 November 2014

Academic Editor: Olivier Darbin

Copyright © 2014 Dan Song et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Infarct size and brain edema following ischemia/reperfusion are reduced by inhibitors of the Na+, K+, 2Cl−, and water cotransporter NKCC1 and by β1-adrenoceptor antagonists. NKCC1 is a secondary active transporter, mainly localized in astrocytes, driven by transmembrane Na+/K+ gradients generated by the Na+,K+-ATPase. The astrocytic Na+,K+-ATPase is stimulated by small increases in extracellular K+ concentration and by the β-adrenergic agonist isoproterenol. Larger K+ increases, as occurring during ischemia, also stimulate NKCC1, creating cell swelling. This study showed no edema after 3 hr medial cerebral artery occlusion but pronounced edema after 8 hr reperfusion. The edema was abolished by inhibitors of specifically β1-adrenergic pathways, indicating failure of K+-mediated, but not β1-adrenoceptor-mediated, stimulation of Na+,K+-ATPase/NKCC1 transport during reoxygenation. Ninety percent reduction of extracellular Ca2+ concentration occurs in ischemia. Ca2+ omission abolished K+ uptake in normoxic cultures of astrocytes after addition of 5mM KCl. A large decrease in ouabain potency on K+ uptake in cultured astrocytes was also demonstrated in Ca2+-depleted media, and endogenous ouabains are needed for astrocytic K+ uptake. Thus, among the ionic changes induced by ischemia, the decrease in extracellular Ca2+ causes failure of the high-K+-stimulated Na+,K+-ATPase/NKCC1 ion/water uptake, making β1-adrenergic activation the only stimulus and its inhibition effective against edema.

1. Introduction

Cellular edema is a dreaded consequence of ischemic stroke. On account of the fixed volume of the skull changes in cellular and extracellular volume can compromise cerebral blood flow and metabolism or result in compression of vital brain structures. Novel potential treatment targets for cerebral edema include the Na+-K+-2Cl− cotransporter NKCC1, a critical mediator of edema formation [1]. Its specific inhibitor, bumetanide, inhibits ischemia-reperfusion-induced edema in experimental stroke after middle cerebral occlusion (MCAO) followed by reperfusion [2–4], and knock-out of NKCC1 reduces brain swelling by one-half following 2 hr of MCAO and 24 hr of reperfusion [5].

Dysregulation of ion homeostasis plays a major role in the formation of brain edema. Brain slices show pronounced swelling (edema) during exposure to highly elevated K+ concentrations [6, 7] and the swelling increases with the extracellular K+ concentration up to ~50 mM [8]. Pronounced increases in extracellular K+ concentrations rapidly occur during brain ischemia together with a massive decrease in extracellular Ca2+ and a more moderate decrease in extracellular Na+ [9]. In adult brain NKCC1 is mainly expressed in astrocytes [10–13]. They are also the cells that show most swelling after exposure to pathologically elevated extracellular K+ concentration [14–16].

NKCC1 is not an active transporter but its operation is driven by ion gradients established by Na+,K+-ATPase activity, making it a secondary active transporter [18–20], which requires ongoing or preceding Na+,K+-ATPase activity in order to function. In turn, function of the Na+, K+-ATPase is critically dependent upon the presence of oxygen
and a metabolic substrate, generally glucose. The astrocytic Na\(^{+}\),K\(^{+}\)-ATPase is normally stimulated by slightly elevated extracellular K\(^{+}\) concentrations [21–23]. The resulting stimulation of K\(^{+}\) uptake requires K\(^{+}\)-activated signaling by endogenous ouabains at low nM concentrations, which includes an increase in free cytosolic Ca\(^{2+}\) concentration ([Ca\(^{2+}\)]\(_{i}\)) evoked by activation of the IP\(_{3}\) receptor [17]. This leads to an uptake of Na\(^{+}\), which is required for concomitant stimulation of the intracellular Na\(^{+}\)-sensitive site of the astrocytic Na\(^{+}\),K\(^{+}\)-ATPase and compensates for the absence of astrocytic Na\(^{+}\) entry during neuronal excitation. In neurons the effect of low nanomolar ouabain concentrations on [Ca\(^{2+}\)]\(_{i}\), is known to be abolished by a blocker of the Na\(^{+}\)-Ca\(^{2+}\) exchanger (NCX) [24]. The same authors also showed ouabain-mediated Ca\(^{2+}\) release from the endoplasmic reticulum in astrocytes but unfortunately no information was provided about potential effects of NCX. This would have been important, because inhibition of astrocytic ouabain signaling and thus Na\(^{+}\),K\(^{+}\)-ATPase function by deficient Ca\(^{2+}\) entry after ischemia/reperfusion-induced depletion of extracellular Ca\(^{2+}\) [9] might inactivate the normally occurring K\(^{+}\)-induced stimulation of Na\(^{+}\),K\(^{+}\)-ATPase activity required for NKCC1 function [17]. This would make NKCC1 stimulation dependent upon β-adrenergic signaling, which also stimulates astrocytic, but not neuronal, Na\(^{+}\),K\(^{+}\)-ATPase activity [23]. It would mean that following ischemia/reperfusion NKCC1 activity would be selectively dependent upon β-adrenergic stimulation. Such dependency might explain the protective effect of β-adrenergic antagonists demonstrated in animal models of CNS ischemia [25–28].

In the present study the increase in brain edema by unilateral MCAO and its abolishment by an NKCC1 inhibitor and a β\(_{1}\)-adrenergic antagonist were confirmed. Moreover, whether the increase occurred during the ischemic period or was delayed until after reoxygenation and whether inhibition of the known pathway for β\(_{1}\)-adrenergic stimulation of cultured astrocytes also prevented edema formation were tested. The inhibitory effect of extracellular Ca\(^{2+}\) deficiency on K\(^{+}\) uptake was tested in two different types of experiments. One of these compared effects of a slightly elevated extracellular K\(^{+}\) concentration and of the β\(_{1}\)-adrenergic agonist dobutamine on uptake of K\(^{+}\) into primary cultures of astrocytes during incubation in a medium with a normal Ca\(^{2+}\) concentration and in a Ca\(^{2+}\)-depleted medium. The other showed that the inhibitory effect of μM concentrations of ouabain on K\(^{+}\) uptake in cultured astrocytes is much less potent in the absence of Ca\(^{2+}\) in the incubation medium.

2. Methods

2.1. Materials. Most chemicals, including isoproterenol, ethacrynic acid, ouabain hydrochloride, the β-adrenergic receptor antagonists, betaxolol (4-(2-cyclopropylmethoxyethyl)-1-phenoxy-3-isopropylaminopropan-2-ol) and ICI118551 (erythro-(±)-(7-methylindan-4-yloxy)-3-isopropylaminobutan-2-ol), the β\(_{1}\)-adrenergic agonist dobutamine, pertussis toxin (PTX), and the PKA inhibitor H-89 (N-[2-(p-bromocinnamylamo)ethyl]-5-isooquinolinesulfonaphthalide) were purchased from Sigma (St. Louis, MO, USA). The EGFR tyrosine kinase inhibitor, Tyrphostin AG 1478 (N-[2(R)-2-(hydroxamidocarbonylmethyl)-4-methyl-pentanoyl]-L-tryptophan methylamide), the metalloproteinase inhibitor, GM 6001 (1,4-diamo-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene); the MEK inhibitor, U0126, (1,4-diamo-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene); and the Src inhibitor, PP1 (4-amino-5-(4-methylphenyl)-7-(t-butyl)pyrazololo[3,4-d]pyrimidine) were obtained from Calbiochem (La Jolla, CA, USA). Horse serum was either drawn from selected animals (Figure 3) or bought from Gibco (Gaithersburg, MD, USA). The surfactant polyol Pluronic F-127 and P-1267 PBFI-AM (124549-23-1,3-benzenedicarboxylic acid, 4,4′-[1,4,10,13-tetraoxa-7,16-diazacyclooctadecane-7,16-diyldis[5-methyoxy-6,2-benzofurandiyld][bis-, tetrakis[acetyloxy]methyl]ester) used for fluorescence determination of intracellular K\(^{+}\) concentration were purchased from Invitrogen (Carlsbad, CA, USA). 42 K was obtained from New England Nuclear, Lachine, Quebec (no longer available). Pentobarbital sodium was obtained from Sinopharm Chemical Reagent Co., Ltd. (Shanghai, China).

2.2. MCAO. All experiments were carried out in accordance with the USA National Institute of Health Guide for the Care and Use of Laboratory Animals (NIH Publications number 80–23) revised 1978, and all experimental protocols were approved by the Institutional Animal Care and Use Committee of China Medical University. The experiments were carried out using rats, because it would have been very difficult to effectively perform MCAO in mice, used routinely for our cultures. In general, rats and mice are believed to react in rather similar manners to brain ischemia. Male Sprague-Dawley rats, weighing 280–320 g, were housed in cages on a 12 h light/dark cycle in a temperature-controlled (23–25°C) colony room with free access to food and water. Focal brain ischemia was induced unilaterally by occlusion of the right middle cerebral artery (MCAO) as previously described by Longa et al. [29] in animals anaesthetized with pentobarbital sodium. A 30 mm segment of 4-0 Ethilon monofilament was gently introduced from the common carotid artery into the internal carotid artery lumen until a slight resistance was felt. The filament had been coated with polylysine, and its tip was rounded by heating. The filament was withdrawn 3 hr after induction of ischemia. The animals were generally decapitated 8 hr after reperfusion, but in some cases (part of Figure 1) before reperfusion, and the brains were removed for measurement of brain edema. Intraventricular injection of drugs or saline (into the control animals) was made 15 minutes before the occlusion. The drugs were gently injected intraventricularly, dissolved in 5 μl physiological saline, at the following concentrations: ethacrynic 50 mM; betaxolol 3 mM; ICI118551 10 μM; H89 500 μM; PTX 20 μM; PP1 1 mM; AG1478 100 μM; GM6001 1 mM; U0126 1 mM. With a brain weight in the rat of 1-2 g the intracerebral concentrations are probably at least 100 times smaller but dependent upon the distribution, which may vary between the individual drugs.
2.3. Determination of Edema. Wet weights (WW) were separately measured in right hemispheres (ischemia side) and left hemispheres (control side) after removal of cerebellum, pons, and olfactory bulbs. Dry weights (DW) were determined after 24 hr heating at 120°C as described by Bigdeli et al. [30], and percentage brain water content in each sample was calculated as \([(WW - DW)/WW] \times 100\). The difference in brain water content between the ischemic and control sides indicates the magnitude of the induced edema.

2.4. Cell Cultures. Primary cultures of astrocytes were prepared from newborn male or female Swiss mice as previously described [31, 32]. The neopallia of the cerebral hemispheres were aseptically isolated, freed of meninges, dissociated by vortexing, filtered twice through nylon meshes, diluted in culture medium, and planted in 60 mm Falcon culture dishes. The culture medium [32] was Dulbecco’s medium or a very slightly modified Dulbecco’s medium [31], both containing 5.4 mM KCl, 1.8 mM CaCl$_2$, 75 mM glucose, and 20% horse serum. The cultures were incubated at 37°C in a humidified atmosphere of CO$_2$/air (5:95%). The medium was exchanged with fresh medium of similar composition on day 3 and subsequently every 3-4 days. At day 3, the serum concentration was reduced to 10%, and after the age.
of 2 weeks, 0.25 mM dibutyryl cyclic AMP (dBcAMP) was included in the medium. This compound increases intracellular cyclic AMP and promotes differentiation in astrocyte cultures derived from newborn brain. Recently the usefulness of astrocyte cultures has been authoritatively reviewed by Lange et al. [33]. Close similarities between our cultures and freshly isolated astrocytes in not only levels but also development of aralar protein and mRNA expression [34] and in gene changes introduced by chronic treatment with fluoxetine [35] support their validity as models of their in vivo counterparts. Moreover, stimulation of glycogenolysis by elevated extracellular K\(^+\), which is essential for its uptake into astrocytes [17], only occurs after treatment with dBcAMP [36].

2.5. Determination of Intracellular K\(^+\) Concentration. Determination of potential increase in intracellular K\(^+\) concentration from its control value in extracellular K\(^+\) concentration or by dobutamine was determined as by Xu et al. [17], using the K\(^+\)-sensing fluorescent drug PBFI-AM. At the start of the experiment astrocyte cultures on coverslips coated with polylysine and placed within a Falcon Primaria culture dish were loaded with 10\(\mu\)M PBFI-AM with 0.2% Pluronic F-127 in phosphate-buffered saline (concentrations in mM: Na\(^+\) 141, K\(^+\) 5.4, Cl\(^-\) 146, PO\(_4\)\(^3-\) 0.44, HCO\(_3\)\(^-\) 4.0, Ca\(^{2+}\) 1.3, Mg\(^{2+}\) 1.3, SO\(_4\)\(^2-\), and glucose 10) for 45 min at 37°C. After 2 times of wash with similar saline, the coverslip was superfused with saline solution with or without Ca\(^{2+}\) for 2 min, after which KCl was added. Subsequently the fluorescence intensity was recorded in each of 20 individual cells for 7 min with 20 sec interval at excitation wavelengths of 340 (F340) and 380 (F380) nm. The ratio F340/F380 is an arbitrary measurement of the intracellular K\(^+\) concentration, and its potential changes during the measurement are an indication of K\(^+\) uptake rates. No calibration was made to obtain absolute values.

2.6. Ouabain Effect on K\(^+\) Uptake Rate in Media with and without Ca\(^{2+}\). Unidirectional net uptake of K\(^+\) was determined by exposing each culture for only 1.00 min (securing initial uptake rates) to serum-free culturing medium containing 42K at 37°C. In order to exclude homoechange between added 42K and intracellular K\(^+\), the cultures had initially been depleted for intracellular K\(^+\) by a 10–15 min incubation in ice-cold (1°C) K\(^-\)-free medium [37]. In order to rapidly reheat the cultures the 1 min incubation was carried out with the cultures floating on the surface of a water bath at 37°C. When ouabain was used it was present from the start of the preincubation.

After the 1 min incubation in the presence of 42K the cultures were washed three times with ice-cold 300 mM sucrose solution. In each wash all adherent fluid in the culture dish was removed with the aid of a fine nozzle connected to a water-suction pump. The whole washing procedure lasted for approximately 8 s. Such a short washing time is essential to prevent a significant decrease of 42K from the cells by passive efflux. The effectiveness of this washing procedure has previously been shown by very low amounts of potassium uptake at 1°C [31]. Subsequently, 1.00 mL of 1.0 M NaOH was added, 42K activity was counted in the cultures and in the incubation media with the aid of a Beckman FL800 gamma counter, and protein content was determined by the conventional Lowry technique [38].

Uptake rates were calculated from the uptake of 42K into the tissues and the specific activities of the media with due consideration of the rapid decay of 42K. The inhibition by ouabain was determined from the differences in uptake rates between cultures containing the inhibitor and cultures of the same batch from which it was absent. A tendency was observed towards a biphasic inhibition by ouabain, reflecting differences between its effect on the \(\alpha_1\) and \(\alpha_2\) subunit of the Na\(^+\),K\(^-\)-ATPase.

2.7. Statistics. The statistical values of the differences between individual groups were analyzed by one-way ANOVA followed by Fisher’s LSD test. The level of significance was set at \(P < 0.05\). GraphPad Prism 6 analysis of the results shown in Figure 3 was performed assuming a biphasic inhibition.

3. Results

3.1. Edema Occurs after Reperfusion. Table 1 shows brain swelling in the ipsi- and contralateral hemispheres induced by MCAO. The determinations were made either immediately after the ischemic period (3 hr) or after the tissue had been reoxygenated for 8 hr. The results show that the edema appears after the reoxygenation with little, if any, edema formation during the ischemic period. This probably reflects insufficient energy to drive the Na\(^+\),K\(^-\)-ATPase during the ischemic insult per se.

3.2. Effect of an NKCCI Inhibitor or \(\beta_1\)-Adrenergic Antagonists. The cotransporter inhibitor, ethacrynic acid, completely

Table 1: Brain water content in MCAO model with and without reperfusion.

|                  | No reperfusion | 8 hr reperfusion |
|------------------|---------------|-----------------|
|                  | Left hemisphere | Right hemisphere | Left hemisphere | Right hemisphere |
| Control          | 77.58 ± 0.20 (n = 5) | 78.05 ± 0.29 (n = 5) | 77.34 ± 0.18 (n = 3) | 77.32 ± 0.14 (n = 3) |
| Ischemia 3h      | 77.25 ± 0.16 (n = 5) | 78.14 ± 0.25 (n = 5) | 77.97 ± 0.17 (n = 8) | 81.28 ± 0.34\(\ast\) (n = 8) |

Water content was calculated as [(wet weight – dry weight)/wet weight] × 100% in rats where MCAO had been performed on the right side. In control rats no significant change occurred with or without reperfusion. In animals with MCAO in the right hemisphere a small apparent increase in water content in this hemisphere after 3 hr of ischemia was not statistically significant, whereas a larger increase after reperfusion marked with \(\ast\) was significant (\(P < 0.05\)). It was also significantly different (\(P < 0.05\)) from the small apparent increase without reperfusion.
Table 2: Brain water content in MCAO model after 3 hr ischemia and 8 hr reperfusion in the right hemisphere under control conditions (only saline injected intraventricularly before the occlusion) and after injection of a NKCC1 inhibitor or β1- or β2-adrenergic subtype-specific antagonists, dissolved in saline.

| Inhibitor       | Left hemisphere | Right hemisphere |
|-----------------|-----------------|------------------|
| Saline          | 77.97 ± 0.17 (n = 8) | 81.28 ± 0.34 (n = 8)* |
| Ethacrynic      | 77.46 ± 0.11 (n = 7) | 78.29 ± 0.76 (n = 7) |
| Betaxolol       | 78.02 ± 0.17 (n = 7) | 78.44 ± 0.58 (n = 7) |
| ICI118551       | 77.78 ± 0.32 (n = 7) | 81.08 ± 0.18 (n = 7)* |

In rats with MCAO in the right hemisphere drugs were added 15 min before and after injection of a NKCC1 inhibitor or β1- or β2-adrenergic subtype-specific antagonists, dissolved in saline.

Table 3: Brain water content in MCAO model after 3 hr ischemia and 8 hr reperfusion in the right hemisphere under control conditions (intracerebral saline only) and after injection of inhibitors of either the β1- or the β2-adrenergic pathway in astrocytes.

| Inhibitor       | Left hemisphere | Right hemisphere |
|-----------------|-----------------|------------------|
| Saline          | 77.97 ± 0.17 (n = 8) | 81.28 ± 0.34 (n = 8)* |
| H89             | 77.00 ± 0.42 (n = 3) | 77.19 ± 0.09 (n = 3) |
| PTX             | 77.19 ± 0.11 (n = 4) | 77.51 ± 0.26 (n = 4) |
| GM6001          | 77.08 ± 0.11 (n = 4) | 77.15 ± 0.13 (n = 4) |
| AG1478          | 77.14 ± 0.11 (n = 3) | 77.27 ± 0.04 (n = 3) |
| U0126           | 77.39 ± 0.10 (n = 4) | 78.22 ± 0.67 (n = 4) |
| PPI             | 77.52 ± 0.26 (n = 5) | 80.04 ± 0.33 (n = 5)* |

In rats with MCAO in the right hemisphere drugs were added 15 min before the occlusion as described in Methods. Water content was calculated as [(wet weight – dry weight)/wet weight] × 100%. In control animals (the same value as in Table 1) an increase in the ipsilateral hemisphere was significant (P < 0.05), as marked with *. This was also the case after treatment with PPI, an inhibitor of Src, an intermediate in β2-adrenergic signaling, but not after administration of any of the other inhibitors, which interrupt β1- but not β2-adrenergic signaling as shown and discussed in Figure 1. Most but not all inhibitors used to delineate the signaling pathways shown in that Figure were tested in this table. Since PPI was the only β2-adrenergic inhibitor tested, an n = 5 was used, whereas each of the other inhibitors, which all act on the same, β1-adrenergic were tested in fewer experiments.

Inhibited the effect of Na+, K+-ATPase/NKCC1 activation following transient ischemia/reperfusion, strongly suggesting that it was due to the increase in extracellular K+ concentration resulting from the ischemia (Table 2). The β1-adrenergic antagonist betaxolol also abolished edema formation, whereas the β2-adrenergic antagonist ICI118551 had no effect, identifying β1-adrenergic stimulation as the cause of the edema.

3.3. Effects of Inhibitors of β1- and β2-Adrenergic Signaling.

The signaling pathways for both β1- and β2-adrenergic signaling H89 have been determined in cultured astrocytes with the aid of specific inhibitors [39]. As shown in Figure 1, phosphorylation of extracellular regulated kinase 1 and kinase 2 (ERK1/2) by isoproterenol is inhibited by H89, an inhibitor of protein-kinase A (PKA) and thus of Gβγ-mediated signaling by isoproterenol. Pertussis toxin (PTX), an inhibitor of the Gβγ-Gα switch occurring in the astrocytic signaling pathway of β1- but not β2-adrenergic signaling [39], has a similar effect. In this pathway Gα activation is followed by an increase in [Ca2+]i, which in astrocytes leads to metalloproteinase-mediated release of a growth factor that transactivates the epidermal growth factor receptor (EGFR). Both the metalloproteinase inhibitor GM6001 and the EGFR inhibitor AG1478 inhibit ERK1/2 phosphorylation. Do so U0126, an inhibitor of ERK1/2 phosphorylation. As can be seen from Table 2 each of these inhibitors also prevents β1-adrenergic edema formation in vivo after ischemia/reperfusion. In contrast, the Src inhibitor PPI that is active in the β2- but not β1-adrenergic signaling [39] had no effect. The consistency between results obtained in cultured astrocytes and the present in vivo results further supports the validity of the used cultures as models of their in situ counterparts. This is important for the studies described below.

3.4. Ca2+- Dependence of K+-Mediated Increase in Intracellular K+ Concentration. Figure 2 shows that in the presence of Ca2+ in the medium addition of 5 mM KCl causes a relatively fast increase in intracellular K+ concentration similar in magnitude to that previously observed [17]. In the absence of extracellular Ca2+ no such increase occurs. In contrast the effect of the β1-adrenergic agonist dobutamine is independent of the presence of Ca2+.

3.5. The Potency of Ouabain Is Reduced in the Absence of Extracellular Ca2+. Figure 3 shows inhibition of 42K uptake by μM concentrations of ouabain, expressed as percentage of the uninhibited rate in cultures incubated either in medium with a normal Ca2+ concentration (1.8 mM CaCl2) or in medium without added Ca2+. Since no Ca2+ chelator was added, this medium is likely to contain traces of Ca2+. The K+ concentration in the medium was 5.4 mM with 42K adding 0.3 mM. Under control conditions (no ouabain present) the uptake rates were identical in the presence and absence of Ca2+ (275, resp., 282 nmol/min per mg protein). However, the potency of ouabain was drastically reduced by ouabain as seen from Figure 3. In both types of media the GraphPad analysis showed that a minor part of the uptake (~20%) is inhibited by the lower ouabain concentrations with high affinity, and a major part of the uptake is inhibited by higher ouabain concentrations. Unfortunately the individual measurements have been lost, preventing calculation of SEM values. However, some statistical information can be obtained from the GraphPad analysis, as discussed in the legend of the figure, and the statistical significance of the difference with and without Ca2+ is obvious at 100 μM ouabain. The potency of ouabain on the fraction with lower affinity was always inhibited by Ca2+ deficiency. However, at the lowest ouabain concentrations there was a tendency towards a negative inhibition, that is, a stimulation, mimicking the stimulatory effect on Na+, K+-ATPase activity normally only observable at low nanomolar ouabain concentrations [17].
4. Discussion

4.1. Brain Edema and $\beta_1$-Adrenergic Antagonists. This study has demonstrated that the ionic alterations evoked by ischemia (increase in extracellular K$^+$ concentration, decrease in extracellular Ca$^{2+}$ concentration) have profound effects on edema formation and its inhibition by $\beta_1$-adrenergic antagonists. The finding that edema does not develop during the ischemic period but only after reoxygenation is consistent with the energy dependence of the Na$^+$,K$^+$-ATPase/NKCC1 transport system and indicates that the MCAO effectively prevented blood supply. It is in agreement with the observation by Goyagi et al. [40] that administration of $\beta_1$-adrenergic antagonist 30 min after the onset of a 2-hour-long ischemic period drastically reduces infarct size and improves neurological deficit score after 7 days. Iwata et al. [27] even found that administration of antagonists specifically of the $\beta_1$-adrenoceptor beginning 60 min after 8 min bilateral carotid artery occlusion combined with hypotension reduced neuronal injury after forebrain ischemia, although motor activity was not improved. Goyagi et al. [25, 26] also found less edema and infarct after administration of $\beta_1$-adrenergic antagonist beginning before the insult, and motor deficit index scores were significantly lower and neuronal survival was better in rats treated with $\beta_1$-adrenoceptor antagonists beginning 30 min before 10 min of spinal cord ischemia [28]. Unfortunately, the Goyagi group also found that although the $\beta_1$-adrenergic antagonists provided long-term improvement of histological outcome, they had no effect on neurological outcome and spatial memory retention 14 days later, tested with administration beginning 30 min before the onset of ischemia and continuing for 24 hrs [26]. However, this does not necessarily indicate failure of $\beta_1$-adrenergic antagonists to improve long-term functional recovery in brain ischemia. This is because $\beta_1$-adrenergic stimulation exerts beneficial effects, such as the stimulation of glycogenolysis, which is essential for formation of memory [41–44]. It may therefore be advantageous to discontinue treatment with $\beta_1$-adrenergic antagonist as soon as extracellular K$^+$ concentration has normalized. This will in the presence of $\beta_1$-adrenergic antagonists ensure that if a beneficial effect of $\beta_1$-adrenergic stimulation were to be present, it would have been evident during the period of treatment.

![Figure 2: Uptake of K$^+$ into primary cultures of astrocytes measured with the aid of the fluorescent drug PBFI-AM as described in Section 2. After incubation of PBFI-AM-loaded cells in saline solution for 45 min and subsequent wash, the cells were perfused either in similar solution with 2 mM CaCl$_2$ or in a solution without CaCl$_2$ for 2 min. From the start of the graphs they were perfused in a solution to which an additional 5 mM KCl or 10 $\mu$M of the $\beta_1$-adrenergic agonist dobutamine had been added at zero time (with a corresponding reduction of NaCl concentration when K$^+$ was added). Results for K$^+$ addition are averages from 60 individual cells on three coverslips and those after addition of dobutamine are from 38 cells. SEM values are indicated by vertical bars. * Statistically significant (P < 0.05) difference from +5 mM K$^+$ or dobutamine.](image1)

![Figure 3: Ouabain induced inhibition of net influx of $^{42}$K into primary cultures of mouse astrocytes. The uptake was determined during a 1.00 min incubation, which provides initial uptake rates. The graph marked by diamonds was obtained in a slightly modified Dulbecco’s medium containing 1.8 mM Ca$^{2+}$ (for further details see Section 2) and that marked by X in a corresponding medium containing no CaCl$_2$. The inhibition was calculated from the ratios between uptake rates in the absence of ouabain and that at the ouabain concentration in question. The calculated inhibitions were analyzed as a function of the ouabain concentration by GraphPad Prism 6, assuming that they are biphasic, which gave the best fit. SEM values for inhibition of cultures incubated at 1.8 mM Ca$^{2+}$ were obtained from the standard errors given in the Graph Pad analysis for, respectively, high and low affinity. For cultures incubated without Ca$^{2+}$ SEM value for the lower concentrations (high affinity) were similarly based on the Graph Pad analysis. A similar procedure could not be used for the low-affinity component, since the total inhibition did not approach 100%, and the computed standard error accordingly was excessively high. Therefore no SEM values are shown for the two highest concentrations, but they must resemble those at the lower concentrations, since the original uptake readings had approximately similar uncertainties at all concentrations. The apparent stimulation at low ouabain concentrations in the absence of Ca$^{2+}$ reflects an ouabain-mediated stimulation of uptake, normally occurring at low nanomolar concentrations [17]. In both graphs 6 cultures from 2-3 different batches had been used for each point.](image2)
antagonist probably mainly be by neuronal uptake. It is unlikely to require ouabain-mediated signaling, since it in astrocytes serves to promote Na+ uptake for stimulation of the intracellular site of the Na+,K+-ATPase [17], whereas neurons increase intracellular Na+ during excitation.

4.2. NKCC1 Antagonists. The demonstrated ability of ethacrynic acid to abolish ischemia/reperfusion-induced swelling is consistent with its inhibition of swelling and uptake of Na+, K+, and Cl− induced in monkey brain cortex slices by a highly elevated K+ concentration [7]. It is an indication that operation of NKCC1 is by far the dominant mechanism for removal of highly elevated extracellular K+ concentrations in brain. This is consistent with the conclusion by Walz and Hertz [45] that the increase in intracellular K+ content caused by elevation of extracellular K+ from 5 to 54 mM is entirely carrier mediated. A potential neuroprotective ability of ethacrynic acid has previously been studied in a combined trauma/hypoxia model of brain injury in the cat and in a small clinical trial [46]. Ethacrynic acid also had toxic side effects, which do not seem to be shared by furosemide and the very specific NKCC1 blocker bumetanide [47]. As already mentioned, bumetanide inhibits edema in experimental stroke following middle cerebral occlusion (MCAO) and subsequent reperfusion [2–4]. In cultured astrocytes it diminishes cell swelling and Na+, K+, and Cl− accumulation after oxygen and glucose deprivation [48] as well as trauma-induced astrocyte swelling [49].

4.3. Ca2+ and Ouabain Signaling. The rates for active K+ uptake in the absence of ouabain (~280 nmol/min per mg protein) are consistent with previously observed rates of K+ uptake in similar cultures [31] and the biphasic effect is explained by binding to two different Na+,K+-ATPase subunits [50]. The drastic decrease in ouabain potency in the absence of added Ca2+ in the medium (Figure 3) is in agreement with observation by Wang et al. [51] that a transmitter-induced rise in cytosolic Ca2+ triggers an increase in K+ uptake in cultured astrocytes, which was abolished by the NCX inhibitors SEA0400 and SN-6. The same astroocyte-specific transmitter also evoked a transient decrease in extracellular K+ in hippocampal slices. Finally, glucose utilization in freely behaving rats in the presence of elevated extracellular K+ concentrations [52] confirms a previously observed stimulation of oxygen consumption rate in brain slices [53, 54]. The threshold concentration of K+ evoking this effect (20 mM) [54] coincides with that causing swelling in brain slices [8] and the stimulation is inhibited by ethacrynic acid [55], indications that it is a metabolic manifestation of K+-stimulated K+ uptake. In the present context it is important that the K+-induced metabolic stimulation is abolished when Ca2+ is excluded from the medium [54].

Although the present observations together with literature data thus strongly suggest that extracellular Ca2+ depletion plays a major role by abolishing K+-induced, but not β1-adrenoceptor-mediated stimulation of the Na+-K+-ATPase/NKCC1 transport system, additional factors may also be involved in edema formation. Thus, the cellular increase in Ca2+, which is the reason for its extracellular decrease, promotes NADH hyperoxidation and electrical dysfunction after anoxia in hippocampal slices [56]. Not only neurons are affected by the Ca2+ overload, since cultured astrocytes rapidly die following anoxia and reperfusion when the gaseous and interstitial ionic changes of transient brain ischemia are simulated, and their death required external Ca2+ [57]. Importantly, brain swelling requires additional fluid uptake across the blood–brain barrier, which similarly expresses NKCC1 [58]. To what extent this may have played a role after the intraventricular injection of β1-adrenergic agonists (or of ethacrynic acid) used in the present study is unknown. Finally, it should be noted that prestroke use of β1-blockers in a thorough study was found not to affect stroke severity or outcome clinically [59]. This could, however, perhaps reflect that patients on continuous β1-blocker treatment might receive doses providing lower intracerebral concentrations than those employed in this study and needed for protection against edema. To counteract edema formation it may be essential to use high doses of β1-adrenergic antagonists until extracellular K+ has normalized. It is unknown how long that takes, but an at least hour-long increase in extracellular glucose level after seizures [60], which also increase extracellular K+ level, might suggest that this could take a long time, especially when astrocytic K+ reaccumulation is inhibited.

5. Conclusions

The beneficial effects of β1-adrenergic inhibition on infarct size and edema in experimental ischemia/reperfusion are convincing, even when added after the onset of ischemia. This is a great advantage for potential clinical use, and it is consistent with the present observation in this study that most or all of the swelling occurs after reperfusion. The study also confirmed an antiedema effect of NKKC1 inhibitors and of β1-adrenergic antagonists and signaling inhibitors, and it presented evidence that abnormal Ca2+ homeostasis resulting from ischemia is the pathophysiological basis for the mechanism by which β1-adrenergic inhibitors can inhibit brain edema after anoxia/reperfusion. This seems to be because Ca2+ deficiency counteracts stimulation of the Na+,K+-ATPase/NKCC1 transport system by elevated extracellular K+, which requires signaling by endogenous ouabains, and is thus dependent on extracellular Ca2+. Accordingly β1-adrenergic receptor activity is left as its only astrocytic stimulus, and it was shown to be independent of the presence of extracellular Ca2+. Even in the presence of a β1-adrenergic antagonist extracellular K+ will eventually be reabsorbed by the neuronal Na+,K+-ATPase, which is unlikely to require extracellular Ca2+, but this will not lead to swelling in adult brain, where NKCC1 is highly enriched in astrocytes.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.
Authors’ Contribution
Dan Song and Junnan Xu contributed equally to this paper.

Acknowledgment
This study was supported by Grant no. 31171036 to Liang Peng from the National Natural Science Foundation of China.

References
[1] B. P. Walcott, K. T. Kahle, and J. M. Simard, "Novel treatment targets for cerebral edema," Neurotherapeutics, vol. 9, no. 1, pp. 65–72, 2012.
[2] Y. Yan, R. J. Dempsey, A. Flemmer, B. Forbush, and D. Sun, "Inhibition of Na⁺-K⁺-Cl⁻ cotransporter during focal cerebral ischemia decreases edema and neuronal damage," Brain Research, vol. 961, no. 1, pp. 22–31, 2003.
[3] E. R. Migliati, M. Amyr-Moghaddam, S. C. Froehner, M. E. Adams, O. P. Ottersen, and A. Bhardwaj, "Na⁺-K⁺-2Cl⁻ cotransport inhibitor attenuates cerebral edema following experimental stroke via the perivascular pool of aquaporin-4," Neurocritical Care, vol. 13, no. 1, pp. 123–131, 2010.
[4] F. Liu, P. Akella, S. E. Benashski, Y. Xu, and L. D. McCullough, "Expression of Na⁺-K⁺-Cl⁻ cotransporter and edema formation are age dependent after ischemic stroke," Experimental Neurology, vol. 224, no. 2, pp. 356–361, 2010.
[5] H. Chen, J. Luo, D. B. Kintner, G. E. Shull, and D. Sun, "Na⁺- dependent chloride transporter (NKCC1)-null mice exhibit less gray and white matter damage after focal cerebral ischemia," Journal of Cerebral Blood Flow and Metabolism, vol. 25, no. 1, pp. 54–66, 2005.
[6] K. A. Elliott and H. M. Pappius, "Water distribution in incubated slices of brain and other tissues," Canadian Journal of Biochemistry and Physiology, vol. 34, no. 5, pp. 1007–1022, 1956.
[7] R. S. Bourke, H. K. Kimelberg, and L. R. Nelson, "The effects of temperature and inhibitors on HCO₃⁻-stimulated swelling and ion uptake of monkey cerebral cortex," Brain Research, vol. 105, no. 2, pp. 309–323, 1976.
[8] H. Lund-Andersen and L. Hertz, "Effects of potassium and of glutamate on swelling and on sodium and potassium content in brain-cortex slices from adult rats," Experimental Brain Research, vol. 11, no. 2, pp. 199–212, 1970.
[9] A. J. Jansen and M. Nedergaard, "Brain ion homeostasis in cerebral ischemia," Neurochemical Pathology, vol. 9, pp. 195–209, 1988.
[10] S. Marty, R. Wehrle, F. I. Alvarez-Leefmans, B. Gasnier, and C. Sotelo, "Postnatal maturation of Na⁺, K⁺, 2Cl⁻ cotransporter expression and inhibitory synaptogenesis in the rat hippocampus: an immunocytochemical analysis," European Journal of Neuroscience, vol. 15, no. 2, pp. 233–245, 2002.
[11] R. A. Deisz, T.-N. Lehmann, P. Horn, C. Dehnicke, and R. Nitsch, "Components of neuronal chloride transport in rat and human neocortex," The Journal of Physiology, vol. 589, no. 6, pp. 1317–1347, 2011.
[12] C. Kanaka, K. Ohno, A. Okabe et al., "The differential expression patterns of messenger RNAs encoding K⁺-Cl⁻ cotransporters (KCC1,2) and Na⁺-K⁺-2Cl⁻ cotransporter (NKCC1) in the rat nervous system," Neuroscience, vol. 104, no. 4, pp. 933–946, 2001.
[13] Y. Yan, R. J. Dempsey, and D. Sun, "Expression of Na⁺-K⁺-Cl⁻ cotransporter in rat brain during development and its localization in mature astrocytes," Brain Research, vol. 911, no. 1, pp. 43–55, 2001.
[14] E. M. Gerschenfeld, F. Wald, J. A. Zadunaisky, and E. D. De Robertis, "Function of astroglia in the water-ion metabolism of the central nervous system: an electron microscope study," Neurology, vol. 9, no. 6, pp. 412–425, 1959.
[15] R. S. Bourke and K. M. Nelson, "Further studies on the K⁺- dependent swelling of primate cerebral cortex in vivo: the enzymatic basis of the K⁺-dependent transport of chloride," Journal of Neurochemistry, vol. 19, no. 3, pp. 663–685, 1972.
[16] M. Moller, K. Mollgard, H. Lund-Andersen, and L. Hertz, "Concordance between morphological and biochemical estimates of fluid spaces in rat brain cortex slices," Experimental Brain Research, vol. 21, no. 3, pp. 299–314, 1974.
[17] J. Xu, D. Song, Z. Xue, L. Gu, L. Hertz, and L. Peng, "Requirement of glycogenolysis for uptake of increased extracellular K⁺ in astrocytes: Potential implications for K⁺ homeostasis and glycogen usage in brain," Neurochemical Research, vol. 38, no. 3, pp. 472–485, 2013.
[18] S. F. Pedersen, M. E. O’Donnell, S. E. Anderson, and P. M. Cala, "Physiology and pathophysiology of Na⁺/H⁺ exchange and Na⁺-K⁺-2Cl⁻ cotransport in the heart, brain, and blood," The American Journal of Physiology—Regulatory Integrative and Comparative Physiology, vol. 291, no. 1, pp. R1–R25, 2006.
[19] D. Liang, S. Bhatta, V. Gerzanich, and J. M. Simard, "Cytotoxic edema: mechanisms of pathological cell swelling," Neurosurgical Focus, vol. 22, no. 5, pp. E2, 2007.
[20] D. Song, J. Xu, L. Hertz, and L. Peng, "Regulatory volume increase in astrocytes exposed to hypertonic medium requires β₁-adrenergic Na⁺/K⁺-ATPase stimulation and glycogenolysis," Journal of Neuroscience Research, 2014.
[21] F. A. Henn, H. Haljamäe, and A. Hamberger, “Glial cell function: active control of extracellular K⁺ concentration," Brain Research, vol. 43, no. 2, pp. 437–443, 1972.
[22] T. Grisar, G. Franck, and E. Schoffeniels, "Glial control of neuronal excitability in mammals: II. Enzymatic evidence: two molecular forms of the Na⁺, K⁺-ATPase in brain," Neurochemistry International, vol. 2, pp. 311–320, 1980.
[23] I. Hajek, K. V. S. Subbarao, and L. Hertz, "Acute and chronic effects of potassium and noradrenaline on Na⁺, K⁺-ATPase activity in cultured mouse neurons and astrocytes," Neurochemistry International, vol. 28, no. 3, pp. 335–342, 1996.
[24] H. Song, E. Karashima, J. M. Hamlyn, and M. P. Blaustein, "Ouabain–digoxin antagonism in rat arteries and neurones," The Journal of Physiology, vol. 592, no. 5, pp. 941–969, 2014.
[25] T. Goyagi, T. Kimura, T. Nishikawa, Y. Tobe, and Y. Masaki, "β₁-adrenoreceptor antagonists attenuate brain injury after transient focal ischemia in rats," Anesthesia and Analgesia, vol. 103, no. 3, pp. 658–663, 2006.
[26] T. Goyagi, T. Horiguchi, T. Nishikawa, Y. Tobe, and Y. Masaki, "Neuroprotective effects of selective β₁ adrenoceptor antagonists, landiolol and esmolol, on transient forebrain ischemia in rats; A dose-response study," Brain Research, vol. 1461, no. 1, pp. 96–101, 2012.
[27] M. Iwata, S. Inoue, M. Kawaguchi, M. Nakamura, N. Konishi, and H. Furuya, "Posttreatment but not pretreatment with selective β₁-adrenoceptor 1 antagonists provides neuroprotection in the hippocampus in rats subjected to transient forebrain ischemia," Anesthesia and Analgesia, vol. 110, no. 4, pp. 1126–1132, 2010.

BioMed Research International
[28] S. Umehara, T. Goyagi, T. Nishikawa, Y. Tobe, and Y. Masaki, "Esmolol and landiolol, selective β1-adrenoceptor antagonists, provide neuroprotection against spinal cord ischemia and reperfusion in rats," *Anesthesia and Analgesia*, vol. 110, no. 4, pp. 1133–1137, 2010.

[29] E. Z. Longa, P. R. Weinstein, S. Carlson, and R. Cummins, "Reversible middle cerebral artery occlusion without craniectomy in rats," *Stroke*, vol. 20, no. 1, pp. 84–91, 1989.

[30] M. R. Bigdeli, S. Haji zadeh, M. Froz zandeh, B. Rasulian, A. Heidianpour, and A. Khoshbaten, "Prolonged and intermittent normobaric hyperoxia induce different degrees of ischemic tolerance in rat brain tissue," *Brain Research*, vol. 1152, no. 1, pp. 228–233, 2007.

[31] W. Walz and L. Hertz, "Ouabain-sensitive and ouabain-resistant net uptake of potassium into astrocytes and neurons in primary cultures," *Journal of Neurochemistry*, vol. 39, no. 1, pp. 70–77, 1982.

[32] B. H. J. Juurlink and L. Hertz, "Astrocytes," in *Neuromethods in Cell Cultures*, A. A. Boulton, G. B. Baker, and W. Walz, Eds., pp. 269–321, Humana Press, Clifton, NJ, USA, 1992.

[33] S. C. Lange, L. K. Bak, H. S. Waagepetersen, A. Schousboe, and M. D. Norenberg, "Primary cultures of astrocytes: their value in understanding astrocytes in health and disease," *Neurochemical Research*, vol. 37, no. 11, pp. 2569–2588, 2012.

[34] B. Li, L. Hertz, and L. Peng, "Aralar mRNA and protein levels in neurons and astrocytes freshly isolated from young and adult mouse brain and in maturing cultured astrocytes," *Neurochemistry International*, vol. 61, no. 8, pp. 1325–1332, 2012.

[35] L. Hertz, D. Song, B. Li et al., "Signal transduction in astrocytes during chronic or acute treatment with drugs (SSRIs, antidepressant drugs, GABA-ergic drugs, and benzodiazepines) ameliorating mood disorders," *Journal of Signal Transduction*, vol. 2014, Article ID 593934, 21 pages, 2014.

[36] L. Hertz and W. E. Code, "Calcium channel signalling in astrocytes," in *Calcium Antagonists: Pharmacology and Clinical Research*, R. Paolotti, T. Godfraind, and P. M. Vankouw, Eds., pp. 205–213, Kluwer Academic, New York, NY, USA, 1993.

[37] L. Hertz, "Inhibition by barbiturates of an intense net uptake of potassium into astrocytes," *Neuropharmacology*, vol. 18, no. 7, pp. 629–632, 1979.

[38] O. H. Lowry, N. J. Rosebrough, A. L. Farr, and R. J. Randall, "Protein measurement with the Folin phenol reagent," *The Journal of Biological Chemistry*, vol. 193, no. 1, pp. 265–275, 1951.

[39] T. Du, B. Li, H. Li, M. Li, L. Hertz, and L. Peng, "Signaling pathways of isoproterenol-induced ERK1/2 phosphorylation in primary cultures of astrocytes are concentration-dependent," *Journal of Neurochemistry*, vol. 115, no. 4, pp. 1007–1023, 2010.

[40] T. Goyagi, T. Horiguchi, T. Nishikawa, and Y. Tobe, "Posttreatment with selective beta adrenoceptor antagonists provides neuroprotection against transient focal ischemia in rats," *Brain Research*, vol. 1343, pp. 213–217, 2010.

[41] M. E. Gibbs, D. G. Anderson, and L. Hertz, "Inhibition of glycolysis in astrocytes interrupts memory consolidation in young chickens," *GLIA*, vol. 54, no. 3, pp. 214–222, 2006.

[42] J. Duran, I. Saez, A. Gruart, J. J. Guinovart, and J. M. Delgado-Garcia, "Impairment in long-term memory formation and learning-dependent synaptic plasticity in mice lacking glycogen synthase in the brain," *Journal of Cerebral Blood Flow and Metabolism*, vol. 33, no. 4, pp. 550–556, 2013.

[43] L. Hertz, J. Xu, D. Song, T. Du, E. Yan, and L. Peng, "Brain glycogenolysis, adrenoceptors, pyruvate carboxylase, Na⁺/K⁺ ATPase and Marie E. Gibbs’ pioneering learning studies," *Frontiers in Integrative Neuroscience*, vol. 7, no. 20, 2013.

[44] L. Hertz, J. Xu, D. Song et al., "Astrocytic glycolysis: mechanisms and functions," *Metabolic Brain Disease*, 2014.

[45] W. Walz and L. Hertz, "Intracellular ion changes of astrocytes in response to extracellular potassium," *Journal of Neuroscience Research*, vol. 10, no. 4, pp. 411–423, 1983.

[46] E. J. Cragoe Jr., N. P. Gould, O. W. Woltersdorf Jr. et al., "Agents for the treatment of brain injury. 1. (Aryloxy)alkanoic acids," *Journal of Medicinal Chemistry*, vol. 25, no. 5, pp. 567–579, 1982.

[47] B. B. Pond, F. Galeffi, R. Ahrens, and R. D. Schwartz-Bloom, "Chloride transport inhibitors influence recovery from oxygen-glucose deprivation-induced cellular injury in adult hippocampus," *Neuropharmacology*, vol. 47, no. 2, pp. 253–262, 2004.

[48] B. Lenart, D. B. Kintner, G. E. Shull, and D. Sun, "Na–K–Cl cotransporter-mediated intracellular Na⁺ accumulation affects Ca²⁺ signaling in astrocytes in an *in vitro* ischemic model," *The Journal of Neuroscience*, vol. 24, no. 43, pp. 9585–9597, 2004.

[49] A. R. Jayakumar, K. S. Panickar, K. M. Curtis, X. Y. Tong, M. Moriyama, and M. D. Norenberg, "Na–K–Cl cotransporter-1 in the mechanism of cell swelling in cultured astrocytes after fluid percussion injury," *Journal of Neurochemistry*, vol. 117, no. 3, pp. 437–448, 2011.

[50] L. Peng, R. Huang, S. Zhang, and L. Hertz, "Ouabain binding kinetics and FXDY7 expression in astrocytes and neurons in primary cultures: implications for cellular contributions to extracellular K⁺ homeostasis?" *Neuron Glia Biology*, vol. 6, no. 2, pp. 127–135, 2010.

[51] F. Wang, N. A. Smith, Q. Xu et al., "Astrocytes modulate neural network activity by Ca²⁺–dependent uptake of extracellular K⁺," *Science Signaling*, vol. 5, no. 218, article ra26, 2012.

[52] O. Darbin, E. Carre, D. Naritoku, J. J. Risso, M. Lonjon, and P. R. Patrylo, "Glucose metabolites in the striatum of freely behaving rats following infusion of elevated potassium," *Brain Research*, vol. 116, no. 1, pp. 127–131, 2006.

[53] E. Dickens and G. D. Greville, "The metabolism of normal and tumour tissue: neutral salt effects," *Biochemical Journal*, vol. 29, no. 6, pp. 1468–1483, 1935.

[54] L. Hertz and M. Schou, "Univalent cations and the respiration of brain–cortex slices," *The Biochemical Journal*, vol. 85, no. 1, pp. 93–104, 1962.

[55] L. Hertz, L. Peng, C. C. Kjeldsen, B. S. O'Dowd, and G. A. Dienel, "Ion, transmitter and drug effects on energy metabolism in astrocytes," in *Non-Neuronal Cells of the Nervous System: Function and Dysfunction*, L. Hertz, Ed., pp. 435–460, Elsevier, Amsterdam, The Netherlands, 2004.

[56] M. A. Pérez-Pinzón, P. L. Mumford, V. Carranza, and T. J. Sick, "Calcium influx from the extracellular space promotes NADH hyperoxidation and electrical dysfunction after anoxia in hippocampal slices," *Journal of Cerebral Blood Flow and Metabolism*, vol. 18, no. 2, pp. 215–221, 1998.

[57] A. Bondarenko, N. Svichar, and M. Chesler, "Role of Na⁺–H⁺ and Na⁺–Ca²⁺ exchange in hypoxia-related acute astrocyte death," *GLIA*, vol. 49, no. 1, pp. 143–152, 2005.

[58] N. Yuen, T. I. Lam, B. K. Wallace, N. R. Klug, S. E. Anderson, and M. E. O'Donnell, "Ischemic factor-induced increases in cerebral microvascular endothelial cell Na/H exchange activity and abundance: Evidence for involvement of ERK1/2 MAP kinase," *The American Journal of Physiology—Cell Physiology*, vol. 306, no. 10, pp. C931–C942, 2014.
[59] S. de Raedt, P. Haentjens, A. de Smedt et al., “Pre-stroke use of beta-blockers does not affect ischaemic stroke severity and outcome,” *European Journal of Neurology*, vol. 19, no. 2, pp. 234–240, 2012.

[60] O. Darbin, J. J. Risso, E. Carre, M. Lonjon, and D. K. Naritoku, “Metabolic changes in rat striatum following convulsive seizures,” *Brain Research*, vol. 1050, no. 1-2, pp. 124–129, 2005.